{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:58:10Z","timestamp":1760385490346},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/inf.0000000000001275","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T16:29:09Z","timestamp":1465662549000},"page":"1215-1221","source":"Crossref","is-referenced-by-count":9,"title":["Rilpivirine as a Treatment for HIV-infected Antiretroviral-na\u00efve Adolescents"],"prefix":"10.1097","volume":"35","author":[{"given":"Johan","family":"Lombaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsak","family":"Bunupuradah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ramapuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ssali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemie","family":"Hoogstoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marita","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.pcl.2012.07.009","article-title":"Pharmacotherapy of pediatric HIV infection.","volume":"59","author":"Rakhmanina","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.332.7551.1183","article-title":"Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.","volume":"332","author":"Menson","year":"2006","journal-title":"Br Med J"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1586\/eri.10.129","article-title":"Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection.","volume":"8","author":"Foster","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpedi.157.3.249","article-title":"Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.","volume":"157","author":"Murphy","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R8-13-20210202","first-page":"14","article-title":"A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth.","volume":"17","author":"Reisner","year":"2009","journal-title":"Top HIV Med"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1054-139X(99)00052-X","article-title":"Antiretroviral adherence issues among HIV-positive adolescents and young adults.","volume":"25","author":"Belzer","year":"1999","journal-title":"J Adolesc Health"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1542\/peds.109.4.e61","article-title":"Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.","volume":"109","author":"Van Dyke","year":"2002","journal-title":"Pediatrics"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials.","volume":"60","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/QAD.0b013e32835e1554","article-title":"Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies\/ml or less: week 48 phase III analysis.","volume":"27","author":"Molina","year":"2013","journal-title":"AIDS"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials.","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"R18-13-20210202","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: fall 2006.","volume":"14","author":"Johnson","year":"2006","journal-title":"Top HIV Med"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP2358","article-title":"Pre-existing mutations in the rilpivirine phase III trials ECHO and THRIVE: prevalence and impact on virological response.","volume":"18","author":"Vingerhoets","year":"2013","journal-title":"Antivir Ther"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-13-20210202","first-page":"A18","article-title":"Impact of HIV-1 reverse transcriptase E138 mutations selected on rilpivirine drug susceptibility.","volume":"16","author":"Haddad","year":"2011","journal-title":"Antiviral Therapy"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jcph.107","article-title":"Impact of food and different meal types on the pharmacokinetics of rilpivirine.","volume":"53","author":"Crauwels","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1293.2004.00227.x","article-title":"PENTA guidelines for the use of antiretroviral therapy, 2004.","volume":"5(suppl 2)","author":"Sharland","year":"2004","journal-title":"HIV Med"},{"key":"R31-13-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2334-12-21","article-title":"Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.","volume":"12","author":"Nglazi","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R32-13-20210202","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1089\/aid.2012.0215","article-title":"Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.","volume":"29","author":"Evans","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R33-13-20210202","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1542\/peds.2006-0925","article-title":"Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: pediatric AIDS Clinical Trials Group Protocol P1021.","volume":"120","author":"McKinney","year":"2007","journal-title":"Pediatrics"},{"key":"R34-13-20210202","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jac\/dkp322","article-title":"Pharmacokinetics and 48 week efficacy of low-dose lopinavir\/ritonavir in HIV-infected children.","volume":"64","author":"Puthanakit","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R35-13-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11208550-000000000-00000","article-title":"Atazanavir: in pediatric patients with HIV-1 infection.","volume":"14","author":"Deeks","year":"2012","journal-title":"Paediatr Drugs"},{"key":"R36-13-20210202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/INF.0000000000000538","article-title":"Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the pediatric AIDS Clinical Trials Group Protocol 1020A.","volume":"34","author":"Rutstein","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R37-13-20210202","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/INF.0000000000000308","article-title":"Efficacy and safety of darunavir\/ritonavir at 48 weeks in treatment-na\u00efve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).","volume":"33","author":"Flynn","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R38-13-20210202","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":"Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.","volume":"146","author":"Nachega","year":"2007","journal-title":"Ann Intern Med"},{"key":"R39-13-20210202","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/aid.2008.0035","article-title":"Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.","volume":"24","author":"Goldman","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R41-13-20210202","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/apc.2008.0162","article-title":"Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.","volume":"23","author":"Rudy","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"R42-13-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/apc.2009.0198","article-title":"Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.","volume":"24","author":"Rudy","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"R43-13-20210202","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10461-012-0364-1","article-title":"Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV.","volume":"17","author":"MacDonell","year":"2013","journal-title":"AIDS Behav"},{"key":"R44-13-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF03262238","article-title":"Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study.","volume":"14","author":"Wiens","year":"2012","journal-title":"Paediatr Drugs"},{"key":"R45-13-20210202","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10461-014-0859-z","article-title":"Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials.","volume":"19","author":"Agot","year":"2015","journal-title":"AIDS Behav"},{"key":"R46-13-20210202","doi-asserted-by":"crossref","first-page":"20049","DOI":"10.7448\/IAS.18.1.20049","article-title":"Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.","volume":"18","author":"Adejumo","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"R47-13-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.","volume":"59","author":"Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R48-13-20210202","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3851\/IMP2636","article-title":"96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE phase III trials.","volume":"18","author":"Rimsky","year":"2013","journal-title":"Antivir Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:11:52Z","timestamp":1620954712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201611000-00013"}},"subtitle":["Week 48 Safety, Efficacy, Virology and Pharmacokinetics"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001275","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}